Patient-Derived Xenografts to Reduce Cancer Health Disparities
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Leczenie raka pęcherza moczowego, płuc, żołądka lub wątroby
- •Podpisana zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Brak zgody na uczestnictwo w badaniu
- •Pobrany materiał do badania jest uszkodzony lub nieprzydatny
- •Wiek poniżej 18 lat
- •Ciąża
- •Osoby przebywające w więzieniu
- •Osoby niezdolne do wyrażenia świadomej zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 21 Years
- Maximum age
- 100 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
Trial contact
Asst. Clinical Research Coordinator
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.